Gainesville, Ga. – August 29, 2025

Bend Bioscience, a leading US-based contract development and manufacturing organization (CDMO), will invest approximately $20 million in its Gainesville facility expansion in alignment with a projected 10% increase in workforce, deepening its commitment to innovation in pharmaceutical manufacturing in the US while investing in the long-term growth of Georgia’s life sciences sector.

Following the April announcement of new commercial-scale equipment being added to the company’s 120,000-square-foot site, this significant facility expansion is now underway. This initiative includes the buildout of an additional 12,000 square feet to the north end of the facility, representing a 20% increase in manufacturing space and a roughly 10% growth in total site footprint.

This estimated $20 million expansion is anticipated to drive a nearly 10% increase in headcount, which will bring new high-value job opportunities to Gainesville and support the region’s continued emergence as a hub for advanced pharmaceutical manufacturing.

“Bend Bioscience’s specialized expertise advances medical care, supports high-skill jobs, and enhances Georgia’s innovative life sciences industry,” said Deputy Commissioner of Global Commerce Misti Martin, Georgia Department of Economic Development. “When companies choose to expand in Georgia, it speaks to the environment we have built for business. Bend’s growth reflects the opportunities that Georgia’s collaborative and solutions-oriented approach creates for companies growing in communities across the state.”

“Bend Bioscience is proud to deepen our roots in Gainesville,” said Owen Murray, CEO of Bend Bioscience. “We see tremendous value in not only advancing pharmaceutical science but also in investing in the communities that make our mission possible. This expansion strengthens our operational capabilities while creating career opportunities that support Gainesville’s growing biotech ecosystem.”

At the heart of this growth is the installation of state-of-the-art technologies, including a GEA PSD-4 spray dryer and Gerteis roller compactor, which significantly enhance the facility’s ability to produce complex oral dosage forms, including spray dried dispersions and multiparticulate delivery systems. These capabilities complement the expertise at the other Bend Bioscience sites in Florida and Oregon and extend the company’s ability to serve customers from early development to commercial supply—all within the U.S.

In alignment with the expansion, Bend Bioscience will soon be launching a new apprenticeship program in collaboration with Lanier Technical College in Georgia. Designed to prepare students for careers in pharmaceutical sciences, the program will immerse local participants in hands-on training and pharmaceutical manufacturing foundational skills. This initiative reflects the company’s ongoing investment and commitment to workforce development and regional educational advancement.

“By partnering with local institutions and creating new jobs, we’re building a future where cutting-edge pharmaceutical high science and community prosperity go hand-in-hand,” added Murray.

Bend Bioscience’s expanded Gainesville site will serve as a U.S. center of excellence for commercial oral solid dose forms and modified release technologies, with capabilities that include DEA Schedule I-V handling, high-potency compound processing, analytical services, tech transfer, and packaging solutions.

With construction underway and equipment installation aligned to customer timelines, the expanded site is expected to be operational in Q1 of 2027.

About Bend Bioscience

Formed from three specialist CDMOs, the new Bend Bioscience offers bigger solutions and bolder science across small molecule capabilities and enabling technologies. From pre-clinical to commercial scale, Bend provides its clients with the highest levels of service and science, combining the broad capabilities of a large CDMO with the flexibility and speed of an expert partner. We employ our scientific expertise to optimize your formulation designs with a focus on enhanced pharmacokinetics, and deploying enabling technologies such as spray dried dispersions, particle engineering, multi-particulate dosage forms and modified release technologies to affect desired release profiles and in vivo bioavailability. Our partnering approach brings molecules through the clinic, to scaled manufacturing and launch through our network of three specialized, newly expanded facilities in the U.S., from where we offer accelerated solutions for orphan, breakthrough and specialty programs, as well as tech transfer expertise to ease transition from early development to commercial production.

 

Bend Bioscience
Gwen Green
Chief Commercial Officer
e: gwen.green@bendbioscience.com

 

Media Contacts:
Chris Halling
Orientation Marketing Ltd.
t: +44 (0)7580 041073
e: chris.halling@orientation.agency